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Bisphosphonates in the treatment 
of metabolic bone diseases
Atualização sobre bisfosfonatos nas doenças osteometabólicas
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SUMMARY
Osteoporosis is a disease characterized by low bone mass associated with the deterioration of 
microarchitecture, due to an imbalance either in high bone resorption or low bone formation 
or in both, leading to a high risk of fractures. Bisphosphonates are medications which reduce 
the ability of osteoclasts to induce bone resorption and consequently improve the balance be-
tween resorption and formation. There are bisphosphonates approved for the prevention and 
treatment of osteoporosis. Administration can be oral (daily, weekly or monthly) or intravenous 
(quarterly or yearly). These medications are well tolerated and with the correct instructions of 
administration have a good safety profile. Serious side effects, such as, osteonecrosis of jaw is 
very rare. Bisphosphonates are the most prescribed medication for the treatment of osteoporo-
sis. Arq Bras Endocrinol Metab. 2010;54(2):206-12
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SUMÁRIO
Osteoporose é uma doença caracterizada por baixa massa óssea associada à deterioração da 
microarquitetura devido ao desbalanço pela alta reabsorção, baixa formação ou ambas, levan-
do a um alto risco de fraturas. Bisfosfonatos são medicamentos que reduzem a capacidade de 
os osteoclastos induzirem a reabsorção óssea e, consequentemente, melhorar o balanço entre 
reabsorção e formação. Há bisfosfonatos aprovados para prevenção e tratamento da osteopo-
rose. A administração pode ser via oral (diária, semanal ou mensal) ou intravenosa (trimestral 
ou anual). Essas medicações são bem toleradas e, seguindo as recomendações adequadas, 
apresentam alto grau de perfil de segurança. Efeitos colaterais sérios, como osteonecrose de 
mandíbula, são raros. Bisfosfonatos são as medicações mais prescritas para o tratamento da 
osteoporose. Arq Bras Endocrinol Metab. 2010;54(2):206-12
Descritores
Bisfosfonatos; mecanismo de ação; tratamento da osteoporose; efeitos colaterais
IntRODUctIOn
Osteoporosis is defined as a metabolic bone disease characterized by low bone mass associated with 
the deterioration of bone microarchitecture, leading to 
increased risk of fragility and consequently fractures (1).
The uncoupling of bone remodeling is involved in 
the pathophysiology of osteoporosis, with increased re-
sorption and reduced bone formation. Bone remodeling 
is defined as a coupled process between bone resorption 
(performed by osteoclasts derived from hematopoietic 
cells in a process lasting 3 weeks on average) and bone 
formation (promoted by osteoblasts which are cells de-
rived from mesenchymal precursors and this process 
takes 3 to 4 months to be completed) (2). In this regard, 
drugs that decrease bone resorption, the antiresorptives, 
are a form of treatment for osteoporosis among which 
the bisphosphonates are the most widely used.
MechAnISM Of ActIOn
Bisphosphonates are synthetic pyrophosphate ana-
logues with two phosphate groups that bind hydroxy-
apatite with high affinity. The central carbon binds the 
R1 side chain, often a hydroxyl group, which binds 
calcium and allows for more stable interaction with 
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the bone matrix (3). The R2 side chain gives each 
bisphosphonate its characteristic properties and po-
tency. Bisphosphonates can be classified based on the 
presence or absence of a nitrogen atom in the R2 side 
chain. Nitrogen-containing bisphosphonates (alendro-
nate, risedronate, ibandronate, and zoledronic acid) 
are more potent inhibitors of osteoclast action. These 
side-chain differences explain, in part, differences be-
tween the aminobisphosphonates: their affinity and ad-
herence to the hydroxyapatite surface; their diffusion 
into bone; their displacement from this adherence and 
physiochemical binding when bisphosphonates are dis-
continued (offset); and the differences in their ability 
to inhibit the mevalonic acid pathway enzyme, farne-
syl pyrophosphate synthetase (FPPS) (4). Non-amino 
bisphosphonates disrupt the ATP metabolic pathway in 
osteoclasts that leads to osteoclast apoptosis, while the 
amino bisphosphonates impair FPPS. This inhibitory 
effect on FPPS leads to reduced osteoclast capacity to 
prenylate specific intracellular proteins necessary for 
normal osteoclastic cell function (5). The end result is 
a reduced ability of osteoclasts to induce bone resorp-
tion and to induce programmed cell death (apoptosis) 
of osteoclasts (Figure 1).
Bisphosphonates are not metabolized by pyrophos-
phatases. They have very high affinity for bone surface. 
What does not bind to bone is excreted in the urine 
unchanged (6,7). Bisphosphonates are poorly absorbed 
by the gut, with less than 1% bioavailability after oral 
administration (8). This poor absorption is related to 
the heavy negative charge of the bisphosphonate mole-
cule, which makes transport across lipophilic cell mem-
branes difficult. What is absorbed usually has a power-
ful effect on bone turnover. Up to 50% of the absorbed 
or intravenously administered dose is quickly taken up 
by the skeleton (9). 
Bisphosphonates have an extremely high affinity 
for bone, and bone is almost the exclusive tissue that 
takes up bisphosphonates. This selective tissue uptake 
is due to two major and distinctly different reasons: 1) 
Bisphosphonates bind to the denuded bone resorptive 
cavity as a consequence of osteoclastic removal of bone 
tissue during remodeling (physiochemical effect); 2) 
Only phagocytic cells (osteoclasts and macrophages) 
can take up bisphosphonates (cellular effect).
Recent data suggest that bisphosphonates increase 
serum osteoprotogerin (OPG) levels (an osteoblast-
derived protein) and that these increases are correlated 
with increases in bone mineral density (BMD) (10).
Fractures are the most important clinical manifesta-
tion of osteoporosis and can cause substantial morbidity 
(11) and mortality (12). Because of this, any available 
anti-osteoporotic drug needs to clearly demonstrate its 
efficacy in reducing fracture risk. Treatment with anti-
osteoporotic drugs such as bisphosphonates not only 
increases BMD but also significantly reduces vertebral 
fracture relative risk by as much as 40%-50% (13,14). 
There is evolving evidence that patients may pre-
fer a weekly or monthly bisphosphonate formulation 
over the fracture-proven daily dosing formulation (15). 
Better compliance and adherence to therapy may re-
sult in better outcomes (e.g., fracture risk reduction) 
for some patients than for those who are less compliant 
with their medication (16). In the real world of clinical 
practice having choices is good.
Specific bisphosphonate molecules approved for the 
treatment of osteoporosis are: 
1) Alendronate (10 mg/day and 70 mg/week): 
alendronate is the most used amino-bisphosphonate 
and the first to be approved by the FDA for treatment 
of postmenopausal osteoporosis. An observational trial 
with alendronate followed patients for up to 10 years. 
It reduces the incidence of vertebral fracture, non-
Osteoclast apoptosis
Osteoblasts (formation)
Osteoclast 
(resorption)
Bone matrix
Bisphosphonate 
molecule
figure 1. Bisphosphonates are rapidly incorporated to mineralized bone 
matrix. During bone resorption they are captured by osteoclasts. When 
inside these cells, bisphosphonates induce an inhibition of their function 
by disrupting the ATP metabolic pathway and by impairing the enzyme 
FPPS (for amino-bisphosphonates), disorganizing their cytoskeletal. These 
effects decrease osteoclast activity and induce their apoptosis, interrupting 
local bone resorption. 
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vertebral and proximal femur. In the alendronate data 
set, there have been two extension studies. The first, 
an extension of the initial phase III study (17), with 
10-year’s data published (18). The second, an exten-
sion study of the alendronate-FDA registration study, 
the fracture intervention trial (FIT), with the 10-year 
data given the name of FLEX (19). 
2) Risedronate (5 mg/day and 35 mg/week, oral-
ly): in the risedronate clinical trial data set, there are 
5-year data in which a subset from the original multi-
national group was maintained on placebo and anoth-
er was maintained on risedronate (20). New incident 
vertebral fractures continued to be reduced during the 
4th and 5th year in the treated group, which provides 
evidence of long-term fracture benefit over 5 years of 
treatment. More recently, Delmas and cols. (21) com-
pared risedronate 150 mg/month with risedronate 
5 mg/day. Based on comparisons with the historical 
control group, monthly risedronate was similar to the 
5 mg/day dose in reducing the risk of new vertebral 
fractures during the first year of treatment. 
3) Ibandronate (2.5 mg/day orally, 150 mg/month 
orally, every 3 months intravenously): ibandronate 
has been shown to increase BMD (22). In this study 
(MOBILE), women receiving 150 mg/month oral 
ibandronate exhibited significantly larger increases in 
lumbar spine (LS) BMD compared with women receiv-
ing ibandronate 2.5 mg/day orally (6.6% versus 5.0%, 
P < 0.001). Another study (BONE) demonstrated that 
daily ibandronate therapy (2.5 mg orally) reduced ver-
tebral fracture risk in postmenopausal women (23). Ad-
ditionally, a post-hoc analysis found that ibandronate 
decreased the risk of non-vertebral fracture in a high-
risk subgroup of patients with femoral neck T-score 
≤ 3.0 (24). Further trials revealed that ibandronate 150 
mg/month orally and ibandronate 3 mg quarterly in-
travenously (IV) resulted in greater increases in BMD 
compared with the daily oral regimen (22). A post-hoc 
analysis from DIVA evaluated the efficacy of ibandro-
nate intra venous on non-vertebral fracture reduction. 
The relative risk reduction was of 43% versus the oral 
formulation (25). These monthly and IV regimens are 
the currently FDA-approved doses in the USA and 
both of them are already available in Brazil too. 
4) Zoledronic acid (5 mg/year intravenous infu-
sion): HORIZON Trial reported that a yearly zole-
dronic acid infusion (5 mg/year) significantly reduced 
the risk of vertebral fractures, hip fractures, all non-ver-
tebral fractures and clinical vertebral fractures compared 
with placebo in postmenopausal women with osteo-
porosis (26). The HORIZON recurrent fracture trial 
which evaluated clinical fracture incidence in a group of 
men and women who received zoledronic acid infusion 
within 90 days after surgical repair of a low-trauma hip 
fracture, reported significant reductions in overall clini-
cal fractures and in clinical non-vertebral fractures but 
not in new hip fractures. A mortality relative risk reduc-
tion of 28% was observed in the treatment group (27).
5) Pamidronate (60 mg IV every 3 months): Pami-
dronate has not been approved by the FDA for treat-
ment of osteoporosis, but it significantly increases bone 
mass. In a small study with 61 patients, mean follow-up 
duration of 4.3 years, pamidronate compared with oral 
bisphosphonate (alendronate 70 mg/week or risedro-
nate 35 mg/week) showed to be a good option for 
patients who do not tolerate oral bisphosphonates (28) 
and who do not have access to zoledronic acid due to 
its high cost. There are no data about fracture protec-
tion with this regimen. There is a summary of bisphos-
phonates available in table 1.
table 1. Summary of the effects of different bisphosphonates on fracture 
risk reduction, when given with calcium plus vitamin D for postmenopausal 
women with osteoporosis
Vertebral 
fracture
non-vertebral 
fracture
hip  
fracture
Alendronate A A A
Ibandronate A A NAE
Risedronate A A A
Zoledronate A A A
Pamidronate NAE NAE NAE
A: Approved. NAE: not adequately evaluated.
Adapted from reference 29.
BISphOSphOnAteS – SIDe effectS
Although bisphosphonates are usually well-tolerated 
when administered appropriately, several side effects are 
described with variable morbidity. We review here the 
most frequent safety concerns related to bisphospho-
nate therapy.
Gastrointestinal (GI) symptoms are the most fre-
quent side effects attributed to bisphosphonate use. 
They occur in about 20%-30% of the patients, usually 
within the first weeks of therapy (30). Experimental 
studies have previously demonstrated that these drugs 
are able to promote upper gastrointestinal injury, espe-
cially in the context of preexisting esophageal irritation, 
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repeated daily exposure, and dyspepsia (31). Bisphos-
phonates are mostly related to esophageal irritation and 
ulceration with rarer reports of esophageal perforation 
or upper gastrointestinal bleeding. Patients complain of 
heartburn, nausea, and upper abdominal or chest pain 
(32). Although frequently related to bisphosphonate 
use, in prospective, randomized, placebo-controlled 
clinical trials with oral bisphosphonates, there were no 
significant differences in GI side effects between pa-
tients treated with oral bisphosphonates or placebo. 
Most patients reporting GI intolerance to bisphos-
phonates are able to continue on the same drug (33); 
however, Hamilton and cols. (32) demonstrated that 
76% of the patients who discontinued the use of rise-
dronate did so because of gastrointestinal side effects 
(32). No differences in the incidence of gastrointestinal 
side effects between daily and weekly or monthly dos-
ing groups in clinical trials were observed (34). This 
observation may be possibly attributed, at least in part, 
to improper administration, reporting bias of side ef-
fects, or background incidence of GI disorders. 
Regardless of the reason for the GI events some pa-
tients with GI symptoms may become ineligible to con-
tinue oral bisphosphonates therapy and must therefore 
be considered candidates for other formulations, or 
even other drugs for osteoporosis. As intravenous (IV) 
bisphosphonates do not accumulate in the GI tract they 
can be offered as an alternative for patients with intoler-
able GI side effects with oral drugs.
By inhibiting osteoclast action on bone turnover 
bisphosphonates can induce modest, transient, decreases 
in serum calcium levels, with consequent PTH elevation. 
In calcium- and vitamin D-replete patients such variations 
are not associated to symptoms. In patients with hypo-
parathyroid or in vitamin D-deficient patients, however, 
symptomatic hypocalcemia may be observed, especially 
with intravenous, highly-potent bisphosphonates (24). 
Before treatment with a bisphosphonate, particularly with 
an intravenous agent, it is prudent to measure serum cal-
cium and vitamin D levels appropriately correcting even-
tual deficiencies before starting antiresorptive treatment.
Transient flu-like symptoms (acute-phase reaction) 
sometimes occur during IV bisphosphonate therapy 
and rarely after oral therapy (33). Acute-phase reac-
tion (APR) is characterized by low-grade fever, myal-
gia, headache, arthralgias, bone pain, and nausea. It 
more often occurs in patients not previously exposed to 
bisphosphonates; recurrence of symptoms during sub-
sequent infusions is unlikely. APR seems to be related 
to rapid and transient release of proinflammatory cyto-
kines from circulating T-cells (34).
Non-healing lesions of the jaw usually following in-
vasive dental procedures (named osteonecrosis of the 
jaws − ONJ) have been reported in patients in use of 
bisphosphonates. Most of those patients (95%) were 
receiving high-doses of intravenous bisphosphonates 
(zoledronic acid or pamidronate) for cancer-related 
bone disease. Only a small number of patients were 
receiving treatment for Paget’s disease or osteoporo-
sis. Additional risk factors appear to be history of lo-
cal trauma, dental procedures, or dental infection. The 
impact of other factors such as smoking and underlying 
systemic conditions like diabetes mellitus, remains to be 
determined (35). The pathogenesis is still unknown. 
Although hypothesized as a possible etiology to the 
problem stronger reduced bone turnover could not be 
demonstrated in these patients as a risk factor (30). 
For patients in use of bisphosphonate therapy (es-
pecially IV bisphosphonates) management is targeted 
to minimize risk by eliminating active sites of infection 
(minimizing the need for future dentoalveolar proce-
dures). Whenever necessary, it is prudent to consider 
conservative alternatives to surgical procedures, with 
local and systemic antibiotics and minimal bone ma-
nipulation. In case of diagnosed ONJ the best measure 
is to discontinue bisphosphonate therapy, if possible, 
until osteonecrosis heals (35). 
Bisphosphonates generally have been shown to have 
a benign cardiovascular safety profile. Data from the 
HORIZON-Pivotal Fracture Trial, however, suggested 
an increased risk of atrial fibrillation (AF) with use of 
zoledronic acid (24). This study was a double-blind, 
placebo-controlled trial in women with postmenopaus-
al osteoporosis randomized to receive IV zoledronic 
acid (5 mg) or placebo at baseline, at 12 months, and 
24 months. A significant reduction in new vertebral 
and hip fractures was demonstrated. Additional analysis 
of cardiovascular adverse events during the study, how-
ever, showed an increased incidence of AF with zole-
dronic acid versus placebo (1.3% vs. 0.4%; P < 0.001). 
The significance of those findings must subsequently be 
confirmed, since the trial was not designed to examine 
the occurrence of arrhythmias. In the HORIZON − 
Recurrent Fracture Trial, a randomized, double-blind, 
placebo-controlled trial, 1,065 patients with recent 
low-trauma hip fracture received annual infusions of 
zoledronic acid 5 mg and 1,062 received placebo. The 
median follow-up was 1.9 year and the incidence of 
new clinical fractures was significantly reduced in the 
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group receiving the drug. Careful evaluation of atrial 
fibrillation showed no differences between the 2 treat-
ment groups in the study (26). Thus, even in a higher 
risk population such as this one, no arrhythmogenic ef-
fect of zoledronic acid has been identified. 
Other effects are related to bisphosphonate use. In-
flammation of ocular structures, allergic manifestations, 
and abnormal tests of liver function have been reported. 
These effects are generally mild and self-limited (30). For 
some intravenously administered bisphosphonates renal 
toxicity has been described (36), suggesting the need for 
renal function testing before and during treatment, dose 
reductions for mild-to-moderate renal impairment, and 
caution for patients with severe renal dysfunction.
BISphOSphOnAte theRApY AnD OtheR 
SItUAtIOnS Of BOne lOSS 
Glucocorticoids (GC), when continuously used, are as-
sociated with significant side effects, such as bone loss 
and increased fracture risk, clinically evident within 
3 months of starting GC (37). The pathophysiology 
of glucocorticoid-induced bone loss and fracture is 
multifactorial; an important related mechanism is os-
teoblastic dysfunction (38). Bone resorption seems to 
be enhanced as GC can dose-dependently reduce os-
teoprotegerin (OPG) and increase RANKL expression 
with resulting enhanced osteoclastogenesis. In addition 
to their antiresorptive effects, bisphosphonates inhibit 
osteoblast and osteocyte apoptosis (with prolongation 
of their lifespan) induced by GC (39). In patients in 
use of GC treatment with alendronate 5 or 10 mg/day 
preserved bone density reducing the risk of morpho-
metric vertebral fractures (38). Risedronate (40) and 
zoledronic acid (37) are also indicated prevention and 
treatment for glucocorticoid-induced osteoporosis.
Bisphosphonate treatment prevents bone loss in-
duced by immunosuppressive therapy following organ 
transplantation by reducing fracture risk (41). Similarly, 
bisphosphonate therapy is used to blunt bone loss fol-
lowing endocrine ablative therapy with aromatase in-
hibitors in women with breast cancer (42) or GnRH 
therapy for men with prostate cancer (43). 
hOw lOng ShOUlD we cOntInUe 
BISphOSphOnAte tReAtMent?
The half-life of alendronate is similar to that of bone 
mineral, approximately 10 years (18). Thus, skeletal 
effects of alendronate and other bisphosphonates may 
last for long periods after discontinuation of treatment. 
This has led some to suggest a “drug holiday”, which is 
a temporary discontinuation of the drug during which 
patients would still be protected from increased bone 
turnover and fractures (44). Some reports have de-
scribed rather unusual fractures that have also exhibited 
problems with healing in cases where the possibility of 
oversuppression by bisphosphonates seemed to be the 
cause (45,46). However, these reports were unable to 
establish a definitive cause-and-effect relation between 
the fractures and bisphosphonate therapy. Data about 
the evolution of bone turnover markers right after dis-
continuation are lacking, which limits the observation 
about the persistence of the inhibition of bone turnover 
during the first months after discontinuation of the 
drug. However, recent studies (18,19) showed that the 
levels of bone turnover markers increased within a year 
after discontinuation of therapy, but below the pre-
treatment values. A recent randomized controlled trial 
of 1,099 women who received alendronate for a mean 
of five years found similar risk of fracture for the next 
five years among patients who were randomized to pla-
cebo versus continued treatment (18). Other trials with 
long-lasting use of alendronate (17) and risedronate 
(47) have not observed a higher risk of severe adverse 
effects either. Data from our own experience, following 
40 osteoporotic patients who had their bisphosphonate 
treatment discontinued after 5 years, in comparison to 
patients still in use of alendronate 10 mg/day, dem-
onstrated no evidence of excessive bone turnover sup-
pression with elevation of bone resorption (CTX) and 
formation (P1NP) markers during the follow-up (48). 
About 45% of the patients suffered clinically-evident 
bone loss after 1 year, with 5.2% of bone loss in the 
control group (p < 0.001). These data suggest that a 
temporary discontinuation of bisphosphonates after 5 
years of treatment does not seem necessary, and does 
not seem to be safe either, especially for patients with 
high fracture risk. 
cOnclUSIOn
Bisphosphonates correct the imbalance in bone remod-
eling that causes bone loss. Their rapid and sustained 
action on bone turnover is extensively studied, with 
protection from both spine and hip fractures very well 
documented. Although some safety issues generate 
concern these drugs are usually well-tolerated show-
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ing low incidence of severe side effects. Such attributes 
make bisphosphonates an important treatment option 
for the prevention and treatment of various forms of 
bone loss, including osteoporosis.
Disclosure: Henrique Pierotti Arantes and André Gonçalves da 
Silva have no conflict of interest. Marise Lazaretti-Castro is a con-
sultant for Sanofi-Aventis and Novartis and participates as prin-
cipal investigator in clinical research trials supported by Merck, 
Sharp & Dohme, Eli Lilly and Pfizer.
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